GSKGlaxoSmithKlineSigning up patients
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Colonic Neoplasms · Neoplasms, Colon
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 892 (planned)
- Started
- Aug 1, 2023
- Main results expected
- Mar 19, 2029
- Fully finished
- Mar 27, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05855200 · record last updated 2026-01-23 · checked 2026-11-09 15:42 UTC